Avantor (AVTR)

NYSE Health Care Life Sciences Tools & Services S&P MidCap 400
$15.47
+0.33 (+2.18%)
Close of Nov 06, 2026 · end-of-day data

AVTR 8-K filings in 2025

Every material Form 8-K Avantor filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.

Briefs in 2025717 on record in all
Latest filing in 2025Dec 18, 2025leadership
High impact (4-5)2of 7 briefs
ToneNegative1Neutral6
leadership 5earnings 1financing 1
Dec 18, 8:17 AM ET

Avantor Appoints Simon Dingemans, Former GSK CFO, to Board Effective January 2, 2026

Neutral leadership Written later 5.027.01

Avantor's Board elected Simon Dingemans as a director effective January 2, 2026, filling the seat left by Jonathan Peacock's resignation effective December 31, 2025. The filing describes Dingemans's prior roles at The Carlyle Group, GSK and Goldman Sachs and sets his standard non-employee director pay, so shareholders gain a new board member but no change in financial results or operations is reported.

  • Simon Dingemans elected director by the Board on December 17, 2025, effective January 2, 2026, with term ending at the 2026 Annual Meeting
  • Filled vacancy created by Jonathan Peacock's resignation from the Board, effective December 31, 2025
  • Annual cash retainer of $95,000 plus restricted stock units with a grant date fair value of $210,000, vesting May 6, 2026
  • Previously served as CFO of GSK plc from 2011 to 2019; the Board determined he meets NYSE independence standards
Read the filing on SEC.gov ↗
Dec 4, 4:29 PM ET

Avantor appoints Sanjeev Mehra to its board of directors

Neutral leadership Written later 5.027.01

Avantor's board elected Sanjeev Mehra, co-founder and managing partner of Periphas Capital, as a director on December 4, 2025. His initial term runs until the 2026 Annual Meeting of Stockholders, and the filing says he meets NYSE and Exchange Act independence standards.

  • Mehra is 66 and was a Goldman Sachs partner from 1998 to 2017; he also serves on the board of OPENLANE, Inc.
  • Non-employee director pay includes a $95,000 annual cash retainer, prorated for 2025, and restricted stock units with a $210,000 grant date fair value.
  • The restricted stock units are scheduled to vest in full one year from the grant date, subject to continued board service.
  • The filing reports no arrangements with other persons for his selection and no material related-party interest.
Read the filing on SEC.gov ↗
Nov 10, 5:11 PM ET

Avantor appoints Mary Blenn as EVP and Chief Operating Officer, effective immediately

Neutral leadership Written later 5.027.01

Avantor named Mary Blenn Executive Vice President and Chief Operating Officer, a newly created role, effective immediately. She will lead manufacturing and supply chain operations and report to President and CEO Emmanuel Ligner. The filing also sets out her pay package, including a $500,000 base salary and a $5,000,000 target equity grant.

  • Mary Blenn appointed EVP and Chief Operating Officer, effective immediately; role is newly created
  • Base salary of $500,000 with a target annual bonus of 75% of base salary
  • Initial equity grant with target grant date fair value of $5,000,000, with $400,000 awarded at her start date and the remainder in February 2026
  • The filing also amends the education description of CEO Emmanuel Ligner and adds committee appointments for director Gregory Lucier effective November 6, 2025
Read the filing on SEC.gov ↗
Oct 29, 6:13 AM ET

Avantor posts $712 million Q3 loss on $785 million impairment; sales fall 5.3%

Negative earnings Written later 2.02

Avantor reported third-quarter 2025 results with net sales of $1.62 billion, down 5.3% from a year earlier, and a net loss of $712 million after a $785 million non-cash goodwill impairment tied to its Distribution unit. The company also announced a new $500 million share repurchase authorization, which it said reflects confidence in its cash generation.

  • Net sales were $1.62 billion, down 5.3%, with an organic decline of 4.7%
  • Net loss was $712 million, or $1.04 per diluted share, including the $785 million goodwill impairment; adjusted EPS was $0.22 versus $0.26 a year earlier
  • Operating cash flow was $207 million and free cash flow was $172 million for the quarter
  • Board authorized a $500 million share repurchase program
Read the filing on SEC.gov ↗
Oct 14, 4:46 PM ET

Avantor amends credit facilities with $1.4 billion revolver and new euro term loans

Neutral financing Written later 1.011.022.038.01

Avantor's borrowing subsidiary signed an amendment on October 9, 2025 that sets up $1.4 billion of revolving credit and new euro term loans of €400 million and €550 million, with maturities extending to 2030 and 2032. The new facilities will repay the company's existing A/R facility, which had about $208 million outstanding, and the remaining €250 million of senior first lien notes, which were redeemed on October 10, 2025. The filing reflects a debt refinancing and does not report earnings or guidance.

  • Revolving credit commitments total $1.4 billion, with maturity extended to October 9, 2030.
  • New €400 million Euro Term A Loan matures October 9, 2030; new €550 million Euro Term B-6 Loan matures October 9, 2032.
  • PNC-led accounts receivable facility of up to $300 million was repaid and terminated on October 9, 2025.
  • Remaining €250 million of 2.625% notes due 2025 were redeemed on October 10, 2025 at 100% of principal.
Read the filing on SEC.gov ↗
Oct 14, 8:37 AM ET

Avantor chairman Jonathan Peacock to step down from board December 31, 2025

Neutral leadership Written later 5.027.01

Avantor said Chairman Jonathan Peacock will step down as chairman and from the Board and Nominating and Governance Committee on December 31, 2025, and that he did not resign over any disagreement with the company. Board member Gregory L. Summe will become chairman on January 1, 2026, a planned leadership transition rather than a change in reported results.

  • Jonathan Peacock informed Avantor on October 10, 2025 of his decision to step down.
  • Peacock's last day as chairman and director is expected to be December 31, 2025.
  • Gregory L. Summe, a current Board member, will serve as chairman from January 1, 2026.
  • The filing states the departure was not due to any disagreement on operations, policies or practices.
Read the filing on SEC.gov ↗
Oct 3, 8:35 AM ET

Avantor Appoints Gregory Lucier to Board of Directors Effective October 3, 2025

Neutral leadership Written later 5.027.01

Avantor's board elected Gregory Lucier, Executive Chairman and CEO of Corza Medical, as a director effective October 3, 2025, with his term running until the 2026 Annual Meeting of Stockholders. The filing describes this as a board addition with standard non-employee director compensation, and it reports no financial results.

  • Gregory Lucier elected to the board on October 1, 2025, effective October 3, 2025
  • Annual cash retainer of $95,000, prorated for 2025, plus restricted stock units valued at $210,000 at grant
  • Restricted stock units vest in full one year from grant date, subject to continued board service
  • Board determined Lucier meets New York Stock Exchange independence standards
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Avantor filing is on SEC EDGAR ↗. 8-K briefs of other companies →